ArticleDrug and alcohol dependence2026
Buprenorphine utilization following removal of prior authorization requirements in the Kentucky Medicaid population.
Article in Drug and alcohol dependence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo evaluate changes in buprenorphine dispensing for treatment of opioid use disorder (OUD) among Kentucky Medicaid enrollees following the removal of prior authorization (PA) requirements for the transmucosal buprenorphine combination product.
methodsWe analyzed Kentucky Medicaid claims from 1/1/2016 through 6/30/2023 to identify enrollees with OUD during each quarter (Q1/2017-Q2/2023), using a 12-month lookback window. Segmented regression analysis was used for statistical modeling of an interrupted time series (ITS) design to assess changes in the quarterly proportion of enrollees with OUD receiving buprenorphine for OUD treatment, focusing on the effect of PA removal. The effective date of the PA removal was February 22, 2019 and thus Q1/2019 was treated as a roll-in period for policy implementation.
resultsThe quarterly proportion of enrollees with OUD receiving buprenorphine ranged from 0.29 to 0.44 across the study period. Prior to removal of PA requirements for transmucosal buprenorphine, this proportion was increasing at a modest rate (ITS pre-policy slope +0.009; 95% CI 0.008-0.011). The immediate estimated effect of the full PA removal implementation (Q4/2018 to Q2/2019) was a 4-percentage-point increase (level change +0.04; 95% CI 0.03-0.05) followed by a deceleration in growth (slope change -0.006; 95% CI -0.008- -0.005).
conclusionsRemoval of transmucosal buprenorphine PA requirements for Kentucky Medicaid enrollees was associated with a significant immediate increase in buprenorphine dispensing for OUD treatment. Future research should evaluate how post-PA removal trends interact with the Kentucky Medicaid's coverage of methadone for OUD beginning in Q3/2019.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.